KPTI
Price:
$0.595
Market Cap:
$75.08M
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or ...[Read more]
Industry
Biotechnology
IPO Date
2013-11-06
Stock Exchange
NASDAQ
Ticker
KPTI
According to Karyopharm Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 196.52M. This represents a change of -20.27% compared to the average of 246.47M of the last 4 quarters.
The mean historical Enterprise Value of Karyopharm Therapeutics Inc. over the last ten years is 593.79M. The current 196.52M Enterprise Value has changed 3.21% with respect to the historical average. Over the past ten years (40 quarters), KPTI's Enterprise Value was at its highest in in the June 2020 quarter at 1.41B. The Enterprise Value was at its lowest in in the June 2016 quarter at 203.55M.
Average
593.79M
Median
438.04M
Minimum
223.59M
Maximum
1.17B
Discovering the peaks and valleys of Karyopharm Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.19%
Maximum Annual Enterprise Value = 1.17B
Minimum Annual Increase = -6103.74%
Minimum Annual Enterprise Value = 223.59M
Year | Enterprise Value | Change |
---|---|---|
2023 | 223.59M | -29.28% |
2022 | 316.15M | -31.64% |
2021 | 462.49M | -59.69% |
2020 | 1.15B | -1.83% |
2019 | 1.17B | 126.19% |
2018 | 516.67M | 39.02% |
2017 | 371.64M | 22.63% |
2016 | 303.05M | -26.73% |
2015 | 413.60M | -59.24% |
2014 | 1.01B | -6103.74% |
The current Enterprise Value of Karyopharm Therapeutics Inc. (KPTI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
334.07M
5-year avg
663.63M
10-year avg
593.79M
Karyopharm Therapeutics Inc.’s Enterprise Value is greater than X4 Pharmaceuticals, Inc. (79.71M), greater than HOOKIPA Pharma Inc. (-38628737.00), less than Mereo BioPharma Group plc (510.15M), greater than Galera Therapeutics, Inc. (-6823234.00), greater than Acumen Pharmaceuticals, Inc. (104.35M), greater than CytomX Therapeutics, Inc. (53.76M), less than Nuvation Bio Inc. (930.27M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Assembly Biosciences, Inc. (66.55M), greater than Lyra Therapeutics, Inc. (22.80M), less than Replimune Group, Inc. (904.39M), greater than Nuvectis Pharma, Inc. (72.67M), greater than Kronos Bio, Inc. (8.15M), less than Gossamer Bio, Inc. (366.39M), less than Agios Pharmaceuticals, Inc. (1.76B), less than bluebird bio, Inc. (373.49M), less than Intercept Pharmaceuticals, Inc. (915.81M), less than PMV Pharmaceuticals, Inc. (0), greater than Rallybio Corporation (40.53M), greater than Generation Bio Co. (10.47M), greater than Mersana Therapeutics, Inc. (143.59M), greater than Monte Rosa Therapeutics, Inc. (152.76M), less than null (351.25M),
Company | Enterprise Value | Market cap |
---|---|---|
79.71M | $98.92M | |
-38628737.00 | $18.30M | |
510.15M | $589.54M | |
-6823234.00 | $1.63M | |
104.35M | $107.54M | |
53.76M | $83.74M | |
930.27M | $949.12M | |
-6333315.00 | $8.20M | |
66.55M | $93.56M | |
22.80M | $11.28M | |
904.39M | $941.76M | |
72.67M | $89.84M | |
8.15M | $57.32M | |
366.39M | $191.23M | |
1.76B | $1.95B | |
373.49M | $75.74M | |
915.81M | $794.69M | |
0 | $76.07M | |
40.53M | $35.56M | |
10.47M | $71.47M | |
143.59M | $200.12M | |
152.76M | $433.13M | |
351.25M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Karyopharm Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Karyopharm Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Karyopharm Therapeutics Inc.'s Enterprise Value?
What is the highest Enterprise Value for Karyopharm Therapeutics Inc. (KPTI)?
What is the 3-year average Enterprise Value for Karyopharm Therapeutics Inc. (KPTI)?
What is the 5-year average Enterprise Value for Karyopharm Therapeutics Inc. (KPTI)?
How does the current Enterprise Value for Karyopharm Therapeutics Inc. (KPTI) compare to its historical average?